Mutant K-ras Regulates Cathepsin B Localization on the Surface of Human Colorectal Carcinoma Cells  by Cavallo-Medved, Dora et al.
Mutant K-ras Regulates Cathepsin B Localization on the
Surface of Human Colorectal Carcinoma Cells1
Dora Cavallo-Medved*, Julie Dosescu*, Bruce E. Linebaugh*, Mansoureh Sameni*, Debbie Rudy*
and Bonnie F. Sloane*,y
*Department of Pharmacology and yBarbara Ann Karmanos Cancer Institute, School of Medicine, Wayne State
University, Detroit, MI 48201, USA
Abstract
Cathepsin B protein and activity are known to localize
to the basal plasma membrane of colon carcinoma
cells following the appearance of K-ras mutations.
Using immunofluorescence and subcellular fractiona-
tion techniques and two human colon carcinoma cell
lines—one with a mutated K-ras allele (HCT 116) and a
daughter line in which the mutated allele has been
disrupted (HKh-2)—we demonstrate that the local-
ization of cathepsin B to caveolae on the surface of
these carcinoma cells is regulated by mutant K-ras. In
HCT 116 cells, a greater percentage of cathepsin B was
distributed to the caveolae, and the secretion of ca-
thepsin B and pericellular (membrane-associated and
secreted) cathepsin B activity were greater than ob-
served in HKh-2 cells. Previous studies established the
light chain of annexin II tetramer, p11, as a binding site
for cathepsin B on the surface of tumor cells. The
deletion of active K-ras in HKh-2 cells reduced the
steady-state levels of p11 and caveolin-1 and the dis-
tribution of p11 to caveolae. Based upon these results,
we speculate that cathepsin B, a protease implicated in
tumor progression, plays a functional role in initiating
proteolytic cascades in caveolae as downstream com-
ponents of this cascade (e.g., urokinase plasminogen
activator and urokinase plasminogen activator recep-
tor) are also present in HCT 116 caveolae.
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Introduction
Malignant progression involves degradation of extracellu-
lar matrix (ECM) proteins at several steps (e.g., angio-
genesis and the intravasation and extravasation of tumor
cells during hematogenous metastasis) [1,2]. These inva-
sive processes have long been known to be mediated by
enzymatic cascades of multiple proteases and protease
classes [3]. Cathepsin B, a lysosomal cysteine protease,
is one of these enzymes [4]. Cathepsin B is synthesized
as a preproenzyme and is activated in prelysosomal acidic
vesicles (i.e., late endosomes) [5]. This enzyme exhibits
both endopeptidase and exopeptidase activities, with the
latter activity predominant at the acidic conditions found in
lysosomes [6]. Cathepsin B can be stabilized by protein
substrates and has been shown to degrade ECM proteins
in vitro at both acidic and neutral pH [7]. Membrane-associ-
ated cathepsin B can be isolated from a variety of tumor cell
lines [8,9] and membrane-associated cathepsin B activity can
be assayed on living cells in culture (i.e., at neutral pH) [10].
Such observations suggest that cathepsin B may participate
in proteolysis outside the cell. Indeed, Brix et al. [11] have
shown that cathepsin B degrades cross-linked insoluble
thyroglobulin in the lumen of thyroid follicles. Additional
cysteine proteases and proteolytic cascades of cysteine
proteases are also believed to be involved in the degradation
of thyroglobulin and liberation of active thyroid hormones
[11]. Using a confocal assay that we developed to image
proteolysis by living cells, we have established that cathepsin
B degrades type IV collagen at the surface of living cells from
breast [12], colorectal [13], and prostate (Podgorski et al.,
unpublished observations) carcinomas and gliomas [14]. Our
confocal assays implicate proteolytic cascades of more than
one protease class [the cysteine protease cathepsin B, the
serine proteases urokinase plasminogen activator (uPA) and
plasmin(ogen), and matrix metalloproteinase (MMP)] in deg-
radation of type IV collagen [12]. Cathepsin B has been
shown by us and others to activate pro-uPA [15–17], result-
ing in increased invasion of ovarian carcinoma cells [15] and
activation of latent transforming growth factor-h (TGF-h) [17].
During epithelial–mesenchymal transitions, TGF-h–stimulat-
ed ERK signaling regulates genes with functions in cell matrix
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adhesion, cell motility, and endocytosis including several
MMP and ECM components [18]. Elevated TGF-h1 levels
in colon carcinoma cells stimulate cell growth—a process
that is dependent on the mutation of K-ras [19].
In colorectal carcinomas, high levels of cathepsin B
expression are predictive of shorter overall survival [20]. In
parallel with malignant progression to late adenomas and
early carcinomas, cathepsin B moves from the apical region
of the cells to the basal plasma membranes [20]. The
mechanism by which cathepsin B becomes associated with
the basal plasma membrane remains to be elucidated;
however, the basal enzyme is active [21]. The association
of cathepsin B with the basal plasma membrane occurs in
late adenomas and thus coincides with the activation of K-ras
[22]. This is intriguing as cathepsin B has also been shown to
move to the surface of breast epithelial cells that have been
transfected with activated c-H-ras [23]. Nonetheless,
increases in expression of cathepsin B and translocation of
active cathepsin B to the basal membrane are also observed
during the progression of adenomas in Min mice [24], a
model for familial adenomatous polyposis in humans that is
not associated with alterations in K-ras (for review, see Ref.
[25]). The membrane association of cathepsin B, the upre-
gulation of caveolin-1 in colon cancer, and the association of
activated K-ras with colon cancer progression [22] led us to
use two human colorectal carcinoma cell lines that differ in
their expression of mutant K-ras [26] to evaluate potential
interactions among activated ras, cathepsin B, and caveo-
lin-1. Analysis of these cell lines was also of interest due to
the controversy in the literature as to ‘‘which ras rides the
[lipid] raft’’ [27]. The cell surface receptor for the serine
protease uPA, urokinase plasminogen activator receptor
(uPAR), has been localized to caveolae [28] as have MT1-
MMP [29,30] and MMP-2 [30]. Also found in the caveolae is
annexin II tetramer (AIIt) [31,32], a potential binding protein
for such proteases as tissue plasminogen activator (tPA) and
plasmin(ogen) (for review, see Ref. [33]), and procathepsin B
[34]. We demonstrate that active cathepsin B localizes to the
caveolae region of colon cancer cells and that uPA, uPAR,
and AIIt are also associated with caveolae in these cells. On
this basis, we hypothesize that one function of caveolae is to
cluster proteases on the cell surface, thereby facilitating
initiation of proteolytic cascades. Furthermore, we show
reduced expression of caveolin-1, the light chain of AIIt
(p11), and pericellular cathepsin B activity in the colorectal
carcinoma cell line in which K-ras has been disrupted (i.e., in
the less malignant HKh-2 daughter cell line) [26,35].
Materials and Methods
Reagents
The human colorectal carcinoma cell lines HCT 116 and
HKh-2 were kind gifts from Dr. Robert Kerbel (Sunnybrook
Health Science Center, Toronto, Canada) and Dr. Takehiko
Sasazuki (Kyushu University, Higashi, Japan). Dulbecco’s
minimal essential medium (DMEM), Hank’s salt solution,
bovine serum albumin (BSA), antibiotics, glutamine, sapo-
nin, octylglucoside, 2-[N-morpholino]ethanesulfonic acid
(MES), calf thymus DNA, heparin, bisbenzimide dye
H-33258, and all other chemicals, unless otherwise stated,
were from Sigma (St. Louis, MO); fetal bovine serum (FBS)
was from Invitrogen Life Technologies, Carlsbad, CA; anti–
caveolin polyclonal antibodies, monoclonal anti-p36 (mAb 5),
and monoclonal anti-p11 (mAb 148) antibodies were pur-
chased from Transduction Laboratories (Lexington, KY);
rabbit anti–cathepsin B antibodies were produced and char-
acterized in our laboratory [36]; monoclonal anti– lysosomal-
associatedmembrane protein-1 (LAMP-1) (H4A3) antibodies
were from the Developmental Studies Hybridoma Bank
(University of Iowa, Iowa City, IA); polyclonal anti–h-galac-
tosidase (h-gal) antibodies were from Chemicon Technical
Services (Temecula, CA); polyclonal anti-uPA and polyclonal
anti-uPAR antibodies were a kind gift from Dr. Gunilla Hoyer-
Hansen (The Finsen Center, Copenhagen, Denmark);
horseradish peroxidase–labeled goat anti–rabbit and goat
anti–mouse IgG and micro-bicinchoninic acid (BCA) re-
agents were from Pierce (Rockford, IL); fluorescein-conju-
gated affinity-purified donkey anti–rabbit IgG, Texas red–
conjugated affinity-purified donkey anti–mouse IgG, and
normal donkey serum were from Jackson ImmunoResearch
(West Grove, PA); SlowFade antifade reagent was from
Molecular Probes (Eugene, OR); acrylamide and nitrocellu-
lose membranes were from BioRad (Hercules, CA); pre-
stained protein markers and chemiluminescent Western
blotting detection kits were from Amersham Pharmacia
Biotech (Piscataway, NJ); protease inhibitors were from
RocheMolecular Biochemicals (Indianapolis, IN); benzyloxy-
carbonyl-L-arginyl-L-arginine-4-methyl-7-coumarylamide (Z-
Arg-Arg-NHMec) was from Bachem (Torrance, CA); and
the cathepsin B inhibitor, N-(L-3-trans-propyl-carbamoyloxir-
ane-2-carbonyl)-L-isoleucyl-L-proline (CA-074), was from
Peptides International (Louisville, KY).
Cell Culture
HCT 116 and HKh-2 cells were grown in DMEM (low
glucose) with glutamine, supplemented with antibiotics (pen-
icillin/streptomycin) and 10% (vol/vol) FBS in 5% CO2/
humidifed atmosphere at 37jC. Experiments were carried
out when cells were approximately 80% confluent.
Preparation of Caveolae-Enriched Membrane Fractions
Preparation of caveolae-enriched membrane fractions
was performed as previously described [37,38]. Briefly, cells
from 6  100-mm dishes were washed twice with phos-
phate-buffered saline (PBS) and then scraped into 2 ml of
500 mM sodium carbonate, pH 11.0. Cells were homoge-
nized by 10 strokes in a loose-fitting Dounce homogenizer.
The lysates were then sonicated on ice in a 50-W Ultra-
sonicator at 3  20 second pulses and adjusted to equal
protein concentrations. The homogenates were adjusted to
45% sucrose by the addition of 2 ml of 90% (wt/vol) sucrose
prepared in MES-buffered saline (25 mM MES, pH 6.5,
0.15 m NaCl) and placed on the bottom of a 12-ml ultracen-
trifuge tube. The homogenate was overlaid with a 5% to 35%
discontinuous gradient by adding 4 ml of 35% (wt/vol)
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sucrose (in MES-buffered saline containing 250 mM sodium
carbonate) and 4 ml of 5% (wt/vol) sucrose (in MES-
buffered saline containing 250 mM sodium carbonate)
and centrifuged at 39,000 rpm for 18 to 20 hours in a
SW41 rotor (Beckman Instruments, Fullerton, CA) at 4jC.
A light scattering band was observed at the 5% to 35%
sucrose interface. From the top of the gradient, 1-ml
fractions were collected to yield a total of 12 fractions.
Equal volume aliquots from each gradient fraction were
analyzed by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) and immunoblotting.
Preparation of Cellular Extracts
Cells were washed twice with PBS and solubilized in
lysis buffer (10 mM Tris, pH 7.5, 50 mM NaCl, 1% Triton
X-100, 60 mM octylglucoside, 0.1 mM aprotinin, and 1 mM
leupeptin). In the analysis of cathepsin B, cells were
solubilized in a lysis buffer containing 250 mM sucrose,
25 mM MES, pH 7.5, 1 mM EDTA plus 0.1% Triton X-100.
Cell extracts were then passed 10 times through a syringe
with a 20-gauge needle and centrifuged for 5 minutes at
10,000g. The cell homogenate supernatant was recovered
and protein concentrations were quantified using micro-
BCA reagents according to the manufacturer’s instructions.
Equal protein aliquots of each sample were analyzed by
SDS-PAGE and immunoblotting.
SDS-PAGE and Immunoblot Analysis
Samples were separated by SDS-PAGE (7%, 12%, or
15% acrylamide) and transferred to nitrocellulose mem-
branes. Immunoblotting was performed with primary anti-
bodies against cathepsin B (1:4000), caveolin (1:5000), p36
(1:5000), p11 (1:5000), LAMP-1 (1:500), h-gal (1:4000), uPA
(5 mg/ml), uPAR (5 mg/ml), and secondary antibodies conju-
gated with horseradish peroxidase (1:10,000) in Tris-buff-
ered saline (TBS) wash buffer (20 mM Tris, pH 7.5, 0.5 M
NaCl) containing 0.5% Tween 20 and 5% (wt/vol) nonfat dry
milk. We should indicate that although the rabbit anti–h-gal
polyclonal antibody was raised against bacterial h-gal, this
antibody also cross-reacts with the human homologue
(Chemicon Technical Services). We confirmed this prior to
using this antibody for these studies (data not shown). After
washing, specifically bound antibodies were detected by
enhanced chemiluminescence according to the manufactur-
er’s instructions. Quantitation and analysis of bands were
performed using a Luminescent Image Analyzer LAS-1000
Plus (Fujifilm, Stamford, CT) and expressed as arbitrary
units (AU) per square millimeter. Statistical significance
was determined by a two-tailed t-test with assumed equal
variance. * represents a P value less than .05 and **
represents a P value less than .01.
Immunocytochemical Staining and Confocal Microscopy
Cells were grown on glass coverslips to 80% confluency,
and either used for intracellular or surface staining as previ-
ously described [12,39]. Surface staining was carried out at
4jC using nonpermeabilized cells, whereas intracellular
staining was carried out at room temperature using sapo-
nin-permeabilized cells. For surface staining, the primary
antibodies used were rabbit anti–human liver cathepsin B
(5 mg/ml) and mouse anti–human p11 (20 mg/ml), and for
intracellular staining, the antibodies used were rabbit anti–
human caveolin (5 mg/ml) and mouse anti–human p11
(20 mg/ml). Secondary antibodies used were fluorescein-
conjugated affinity-purified donkey anti–rabbit IgG and Tex-
as red–conjugated affinity-purified donkey anti–mouse IgG
(20 mg/ml). Coverslips were mounted upside down with
SlowFade antifade reagent on glass slides and the cells
were observed on a Zeiss LSM 310 microscope (Jena,
Germany) in confocal mode.
Continuous ‘‘Real-Time’’ Cathepsin B Activity Assay
Cathepsin B activity assays on living cells were performed
by the methods described in Linebaugh et al. [10]. Briefly,
cells were grown on 9  22-cm coverslips to 80% conflu-
ency and washed in PBS containing 1.0 mM CaCl2 and 0.5
mM MgCl2, pH 7.4, at 37jC. Cells were then incubated in
‘‘real-time’’ assay buffer [Hank’s balanced salt solution lack-
ing sodium bicarbonate and containing 0.6 mM CaCl2, 0.6
mM MgCl2, 2 mM L-cysteine, 10 mM glucose, and 25 mM
piperazin-N-NV-bis[2-ethanesulfonic acid] (PIPES) (diso-
dium salt), pH 7.0] and 100 mM Z-Arg-Arg-NHMec substrate
for 15 minutes at 37jC. During this time period, cathepsin B
activity was measured in a Shimadzu RF-540 spectrofluor-
ophotometer (Columbia, MD) at an excitation of 380 nm and
emission of 460 nm as the rate of fluorescent product (7-
amino-4-methylcoumarin) formation. This activity repre-
sented pericellular cathepsin B activity and included both
membrane-bound and secreted activities. To measure total
cellular cathepsin B activity, cells in the reaction cuvette were
further treated with 0.1% Triton X-100 and activity was
measured for an additional 5 minutes. The highly selective
cathepsin B inhibitor, CA-074 [40], was then added to all
reactions at a final concentration of 10 mM to confirm that
cathepsin B was responsible for the enzymatic activity
observed during the reaction. Specific activity for cathepsin
B was calculated as picomoles of fluorescent product per
minute per microgram of DNA. Statistical significance was
determined by a two-tailed t-test with assumed equal vari-
ance. * represents a P value less than .05 and ** represents a
P value less than .01.
DNA Assay
Coverslips containing whole cells from ‘‘real-time’’ assays
were stored in 2  DNA assay buffer (200 mM NaCl, 20 mM
EDTA, 20 mM Tris, pH 7.0), freeze-thawed, and sonicated
for 2  10 second pulses. Then 50 ml of cell lysate was
added to 1.0 ml of bisbenzimide solution (one part H2O,
0.001 part 200 mg/ml bisbenzimide dye H-33258, and one
part 2  DNA assay buffer) and incubated at room temper-
ature in the absence of light for 10 minutes. Fluorescence
was measured in a Shimadzu RF-540 spectrofluorophotom-
eter at an excitation of 350 nm and emission of 455 nm.
Relative fluorescence was plotted against a standard DNA
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curve from calf thymus DNA to determine the concentration
of DNA per sample.
Results
Active K-ras Is Associated with Increased Secretion and
Pericellular Activity of Cathepsin B in Human Colorectal
Carcinoma Cell Lines
The colorectal carcinoma cell lines used for these studies
were parental HCT 116 cells, which contain a point mutation
that activates one of the K-ras alleles, and HKh-2 cells, a
subline disrupted at the activated allele [26]. The less tumor-
igenic HKh-2 cells grow more slowly both in vitro and in vivo
[26] and exhibit 80% less degradation of the basement
membrane protein laminin than do HCT 116 cells [35]. Our
initial studies compared the steady-state level of cathepsin B
in these two cell lines. Intracellular cathepsin B was found
predominantly as the two active forms of cathepsin B: the
mature single-chain (31 kDa) isoform and the heavy chain
(25/26 kDa) of the mature double-chain isoform. Interest-
ingly, the expression of active double-chain cathepsin B was
significantly greater in HKh-2 cells than in HCT 116 cells
(Figure 1A). Inactive procathepsin B (43/46 kDa) was not
detected intracellularly in either cell line (data not shown).
Instead, procathepsin B, along with both isoforms of mature
cathepsin B, was secreted from both cell lines (Figure 1A),
with HCT 116 cells secreting higher levels of cathepsin B
than HKh-2 cells. Thus, these data suggest that mutated
K-rasmay contribute to the altered distribution and increased
secretion of cathepsin B observed in HCT 116 cells.
The difference in distribution of cathepsin B between
the two cell lines was further demonstrated by using a
‘‘real-time’’ continuous assay for cathepsin B activity. This
‘‘real-time’’ assay measures the rate of Z-Arg-Arg-NHMec
hydrolysis by living cells grown on coverslips [10]. Cathep-
sin B activity could be measured in both colon carcinoma
cell lines; however, the percentage of cathepsin B activity
that was pericellular (membrane-associated plus secreted)
was significantly greater (approximately three-fold) in the
HCT 116 cells than in the HKh-2 cells (Figure 1B). Along
with observations made in Figure 1A, these data suggest a
role for K-ras in the distribution of active cathepsin B on both
the surface of these colon cancer cells and in their extra-
cellular milieu.
Cathepsin B Associates with AIIt on the Surface of Human
Colorectal Carcinoma Cell Lines
Our previous studies using both breast carcinoma and
glioma cells demonstrate that cathepsin B associates with
the plasma membrane through interactions with p11, the
light chain of AIIt [34]. The AIIt is composed of two light
chains (p11) and two heavy chains (p36). p11 appears to
mediate the interaction of AIIt with the plasma membrane,
and p36 is thought to function as a cell surface receptor to
several proteins (for review, see Ref. [41]). To determine
whether K-ras modulates the expression of AIIt, we com-
pared the intracellular steady-state levels of p11 and p36 in
HCT 116 and HKh-2 cells. Although both cell lines expressed
p11 and p36, HKh-2 cells expressed less p11 (~50%) than
did HCT 116 cells (Figure 2A). In contrast, the intracellular
steady-state levels of p36 were comparable between the two
cell lines (Figure 2A). These results suggest a role for K-ras
in the expression of p11 that may contribute to altered
distribution of cathepsin B in HCT 116 cells.
In our previous studies, the association between cathep-
sin B and p11 was revealed using several techniques,
including interaction of recombinant proteins in vitro, coim-
munoprecipitation from tumor cell membranes with an anti-
body to the annexin II heavy-chain p36, and colocalization on
the tumor cell surface by immunofluorescent surface staining
[34]. Here we used the same surface staining procedure to
illustrate the association of cathepsin B with p11 in HCT 116
cells. HCT 116 cells were chosen to demonstrate this
association due to their higher level of expression of p11
protein. For these studies. we used an established protocol
for staining of surface proteins [39,12] that does not per-
meabilize cells and thus allows one to differentiate cell
surface cathepsin B from lysosomal cathepsin B. The anti–
cathepsin B antibody recognizes both procathepsin B and
the active single-chain and double-chain forms of the
enzymes [36], and thus would not discriminate among the
molecular forms of cathepsin B but would establish that
cathepsin B was present on the cell surface. In HCT 116
cells, surface staining for cathepsin B and p11 was observed
as discrete green and red patches, respectively, on the cell
surface (Figure 2B), a pattern similar to that observed for
cathepsin B and p11 on the surface of BT20 human breast
carcinoma and U87 human glioma cells [34] and for p11 on
human HT1080 fibrosarcoma [42] and human umbilical vein
endothelial cells [43]. The areas of overlap for cathepsin B
and p11 staining on the surface of HCT 116 cells appear
yellow (Figure 2B). Not all cells exhibit surface staining for
either cathepsin B or p11 as also observed in previous
studies by us [34] and others [42,43]. Although the fluores-
cent images for cathepsin B and p11 do not verify a direct
interaction between cathepsin B and p11, they do establish
that the two proteins are present in close proximity on the
surface of HCT 116 tumor cells.
AIIt Associates with Caveolae of Human Colorectal Carci-
noma Cell Lines
Previous studies have localized AIIt to caveolae of endo-
thelial and MDCK cells [31,32]. Here we explored the effects
of K-ras on the association of p11 and p36 with caveolae in
the HCT 116 and HKh-2 cells. Because the levels of p11 in
HCT 116 cells were higher than in HKh-2 cells (cf. Figure 2A),
we analyzed the expression of caveolin-1, a major structural
protein of caveolae, in both HCT 116 and HKh-2 cells. Both
cell lines expressed caveolin-1, but the steady-state level of
caveolin-1 in HKh-2 cells was ~25% lower than HCT 116
cells (Figure 3A).
To isolate caveolae and their associated proteins from
colon carcinoma cells, we employed a well-established
protocol [37] based on the insolubility of caveolae to
carbonate extraction and their specific buoyant density in
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equilibrium sucrose gradients. This procedure separates
caveolae and their associated proteins from > 99.95% of
the total cellular proteins including organelle-specific
markers for endoplasmic reticulum, Golgi, lysosomes, mi-
tochondria, and noncaveolae membranes [31,44,45]. Frac-
tionation of HCT 116 and HKh-2 cells established that the
bulk of caveolin-1 (seen as a and h isoforms) was isolated
in low-density fractions 3 to 6, hereafter designated as
caveolae fractions (Figure 3B). The polyclonal caveolin
antibody used in this study is a general caveolin antibody;
however, we have verified the presence of caveolin-1 in
these cells using a monoclonal caveolin-1 antibody (mAb
C060; Transduction Laboratories, Lexington, KY) (data not
shown). In both cell lines, fractionation studies revealed
that p36, the annexin II heavy chain, was present in caveolae
fractions and in the high-density fractions 7 to 12, hereafter
Figure 1. Differences in the expression, secretion, and activity of cathepsin B in HCT 116 and HKh-2 cells. (A) Conditioned media from HCT 116 and HKh-2 cells
were collected and the cells were solubilized in lysis buffer containing 0.1% Triton X-100. Media and cell lysates (40 g of protein) were analyzed by SDS-PAGE
and immunoblotted with anti –human cathepsin B antibody. Bar graphs represent densitometric analysis of protein bands from at least three experiments
(expressed as AU/mm2); mean ± SD. *P < .05, **P < .01. (B) HCT 116 and HKh-2 cells were grown on glass coverslips to 80% confluency. The pericellular
(membrane-associated and secreted) and total cathepsin B activities in these living cells were measured against Z-Arg-Arg-NHMec substrate (see Materials and
Methods section). Reactions were terminated by the addition of 10 M of the cathepsin B-selective inhibitor, CA-074 [40]. The specific activity for pericellular
cathepsin B was expressed as a percent of the total cathepsin B activity in HCT 116 and HKh-2 cells. The graph is representative of at least three experiments and
presented as mean ± SD. *P < .05.
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designated as noncaveolae fractions (Figure 3B). p11, the
annexin II light chain, was present in noncaveolae frac-
tions of both cell lines and in caveolae fractions of HCT
116 cells, but could not be detected in caveolae fractions
of HKh-2 daughter cells (Figure 3B). These results sug-
gest that active K-ras affects the expression of caveolin-1
and p11 as well as the distribution of p11 to caveolae
fractions in HCT 116 cells.
Double labeling of saponin-permeabilized HCT 116 cells
was performed to further establish an association between
caveolin-1 and p11 in these cells. Permeabilization of HCT
116 cells is required because the caveolin-1 antibody is
Figure 2. Expression of AIIt and its association with cathepsin B in human colorectal carcinoma cells. (A) HCT 116 and HKh-2 cells were solubilized in lysis buffer
containing 1% Triton X-100 and 60 mM octylglucoside. Ten milligrams of protein was analyzed by SDS-PAGE and immunoblotted with anti –human p11 and anti –
human p36 antibodies. Bar graphs represent densitometric analysis of protein bands from at least three experiments (expressed as AU/mm2); mean ± SD. *P < .05,
**P < .01. (B) Surface staining was performed on HCT 116 cells grown on glass coverslips as described in Materials and Methods section. Cells were incubated in
the absence of detergents with primary antibodies, monoclonal anti –human p11 IgG, plus rabbit anti – human cathepsin B IgG. Cells were then incubated with
FITC-conjugated affinity-purified donkey anti – rabbit and Texas red–conjugated affinity-purified donkey anti –mouse IgG plus normal donkey serum. The cells
were observed with a Zeiss LSM 310 microscope in confocal mode at a magnification of  630 under oil immersion. Surface immunostaining for cathepsin B and
p11 is shown in green and red, respectively. Areas of overlap for cathepsin B and p11 staining are shown in yellow on the cell surface. These images are
representative of three experiments. Bar, 20 m.
512 Cathepsin B in Tumor Cell Caveolae Cavallo-Medved et al.
Neoplasia . Vol. 5, No. 6, 2003
Figure 3. Expression of caveolin-1 and its association with AIIt in human colorectal carcinoma cells. (A) HCT 116 and HKh-2 cells were solubilized in lysis buffer
containing 1% Triton X-100 and 60 mM octylglucoside. Ten micrograms of protein was analyzed by SDS-PAGE and immunoblotted with anti –human caveolin-1.
Bar graphs represent densitometric analysis of protein bands from at least three experiments (expressed as AU/mm2); mean ± SD. *P < .05, **P < .01. (B) Equal
amounts of protein for HCT 116 and HKh-2 cells were subjected to subcellular fractionation on a sucrose gradient after homogenization in sodium carbonate buffer,
pH 11.0 (see Materials and Methods section). Fractions were collected from the top of the gradient and equal volume aliquots were analyzed by SDS-PAGE and
immunoblotting. Panels from top to bottom represent fractions from HCT 116 and HKh-2 cells probed with rabbit anti – human caveolin-1 (top), mouse anti –human
p36 (middle), and mouse anti –human p11 (bottom). These are representative of at least three experiments. (C) Intracellular staining was performed on HCT 116
cells grown on glass coverslips, as described in Materials and Methods section. Cells were incubated in the presence of saponin with primary antibodies,
monoclonal anti –human p11 IgG, plus rabbit anti – human caveolin-1 IgG. Cells were then incubated with FITC-conjugated affinity-purified donkey anti – rabbit and
Texas red–conjugated affinity-purified donkey anti –mouse IgG plus normal donkey serum. The cells were observed with a Zeiss LSM 310 microscope in confocal
mode at a magnification of  630 under oil immersion. Intracellular immunostaining for caveolin-1 and p11 is shown in green and red, respectively. Areas of
overlap for caveolin-1 and p11 staining are shown in yellow adjacent to the cytoplasmic face of the cell membrane. These images are representative of three
experiments. Bar, 20 m.
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directed to the N-terminal cytoplasmic tail of the protein
(Transduction Laboratories). Staining for caveolin-1 could
be observed as a discrete green ring adjacent to the cell
membrane (Figure 3C). p11 is an intracellular protein as well
as a caveolar protein, and thus staining for p11 should be
present as red fluorescence throughout the cytoplasm of the
HCT 116 cells. This was indeed the observed pattern of
staining for p11. The HCT 116 cells are small and have large
nuclei, so the extent of intracellular staining for p11 (Figure
3C) can best be appreciated by comparing it with the surface
staining for p11 in nonpermeabilized cells (cf. Figure 2B).
The areas of overlap for caveolin-1 and p11 staining in HCT
116 cells appear as a discrete yellow ring adjacent to the cell
membrane (Figure 3C). Additional staining representing only
p11 can be distinguished as red fluorescence in many cells.
Although these fluorescent images do not verify a direct
interaction between caveolin-1 and p11, they do establish
that the two proteins are present in close proximity to the
inner cell membrane of the HCT 116 cells.
Cathepsin B Associates with Caveolae of Human Colorectal
Carcinoma Cell Lines
Because p11 was present in caveolae of HCT 116 cells,
we analyzed these subcellular fractions for cathepsin B. In
these sucrose density gradients, cathepsin B was distributed
in two populations: one in caveolae fractions and another in
denser noncaveolae fractions (Figure 4A). The predominant
forms of cathepsin B in both populations were the heavy
chain (25/26 kDa) of the double-chain form and the 31-kDa
single-chain form. The presence of active cathepsin B in
caveolae fractions of colon cancer cells indicates that this
enzyme could participate in cell surface proteolytic events.
As a comparison, we also analyzed the subcellular fractions
of HKh-2 cells and found cathepsin B in both caveolae and
noncaveolae fractions. Quantitation of the amount of cathep-
sin B in each fraction as a percent of the total cathepsin B
revealed that the level of cathepsin B in caveolae fractions of
HCT 116 cells was substantially greater than in caveolae
fractions of HKh-2 cells (Figure 4B). Cathepsin B in HKh-2
cells was predominantly localized to noncaveolae fractions
that include lysosomes, whereas in HCT 116 cells, cathepsin
B was comparably distributed in caveolae and noncaveolae
fractions. These data suggest that the activation of K-ras
may alter pathways for the trafficking of cathepsin B to
caveolae.
Cathepsin B is a lysosomal protease; however, in tumor
cells, cathepsin B is also secreted and becomes associated
with the cell surface [4]. To confirm that the presence of
cathepsin B in caveolae fractions isolated from colon cancer
cells was not due to lysosomal contamination during the
isolation procedure, we examined the distribution of an
insoluble lysosomal marker protein, LAMP-1, and a soluble
lysosomal marker protein, h-gal, in the subcellular fractions
of HCT 116 cells. We then compared the distribution patterns
for LAMP-1 and h-gal to those for caveolin-1 and cathepsin B
(cf. Figure 4A). The peak for caveolin-1 was in fractions 3 to
6, whereas the peaks for the two lysosomal marker proteins,
LAMP-1 and h-gal, were in fractions 7 to 11 (Figure 5).
Cathepsin B was distributed bimodally with one peak in
fractions 2 to 6 and another in fractions 7 to 11, confirming
that the presence of cathepsin B in caveolae fractions was
not due to cross-contamination of these fractions with lyso-
somes during the isolation procedure.
Figure 4. Identification of cathepsin B in caveolae of human colorectal
carcinoma cells. (A) Equal amounts of protein for HCT 116 and HKh-2 cells
were subjected to subcellular fractionation on a sucrose gradient after
homogenization in sodium carbonate buffer, pH 11.0 (see Materials and
Methods section). Fractions were collected from the top of the gradient and
equal volume aliquots were analyzed by SDS-PAGE and immunoblotting.
Panels from top to bottom represent fractions 2 to 11 from HCT 116 and
HKh-2 cells probed with rabbit anti-human caveolin-1 (top) and rabbit
anti –human cathepsin B (bottom). These are representative of at least three
experiments. (B) Densitometric analysis of the cathepsin B protein bands (31
+ 25/26 kDa isoforms) from HCT 116 and HKh-2 fractions in (A) was
performed and presented as percent cathepsin B in individual fractions as a
function of the total (sum of fractions 2–11) and percent cathepsin B
distributed into two major fractions: caveolae (sum of fractions 2–6) and
noncaveolae (sum of fractions 7–11).
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uPA and uPAR Associate with Caveolae of HCT 116
Colorectal Carcinoma Cells
A potential role for active cathepsin B in caveolae is the
initiation of proteolytic cascades via activation of pro-uPA
[5,16,17]. uPAR, the receptor for both active uPA and pro-
uPA, has been shown to complex with integrins and caveolin
in tumor cells [28,46] and has been localized to caveolae of
human chondrocytes [47]. uPAR has previously been
detected in HCT 116 and HKh-2 cells and found to be
expressed at levels 50% to 85% lower in HKh-2 cells [35].
Downregulation of uPAR in HKh-2 cells has been shown to
result in the loss of surface uPA/uPAR–dependent activation
of plasminogen [35]. We fractionated both HCT 116 and
HKh-2 cells and analyzed the fractions for uPAR (Figure 6A)
and uPA (Figure 6B). Both uPAR and uPA were present in
caveolae fractions of HCT 116 cells and in noncaveolae
fractions, as neither protein is exclusive to caveolae. Quan-
titation of the fractions revealed that the percent distribution
of uPAR between caveolae and noncaveolae fractions was
similar in both HCT 116 and HKh-2 cells (Figure 6A). The
amount of uPAR is, however, substantially less in HKh-2 cells
as also shown by others [35]. In contrast, quantitation of uPA
revealed that the amount of uPA in the caveolae fractions as
a percent of the total uPA was dramatically greater in HCT
116 cells compared to HKh-2 cells. Interestingly, the uPA
distribution pattern between caveolae and noncaveolae frac-
tions in HCT 116 and HKh-2 cells closely resembled that
observed for cathepsin B in these cells (cf. Figure 4B). These
data suggest that K-rasmay also affect the trafficking of uPA
to caveolae of these colon cancer cells.
Discussion
Upregulation of cathepsin B expression and activity and
redistribution of cathepsin B to the cell surface are typical
characteristics observed in tumor cells (for review, see Ref.
[48]). A correlation between the expression and activity of
cell surface cathepsin B and the hydrolysis of ECM proteins
has also been revealed. Thus, altered trafficking of cathepsin
B to the plasma membrane of tumor cells implies a functional
role for this enzyme in tumor invasion. Although cathepsin B
has been detected on the surface of many human carcino-
mas, in the present study, we identify caveolae as sites for
association of active cathepsin B with the cell surface of
human colon cancer cells. Furthermore, we show that the
association of cathepsin B with caveolae is regulated by the
activation of K-ras.
Multiple genetic alterations have been associated with
colorectal tumorigenesis in humans including the activation
of the K-ras protooncogene [49, 50]. The disruption in the
mutant K-ras allele in HKh-2 cells caused a loss in their
capacity for anchorage-independent growth and tumorige-
nicity in nude mice compared to HCT 116 cells [26,51]. In the
present study, we observed differences in cathepsin B
expression, secretion, and activity between HCT 116 and
HKh-2 cells. The intracellular steady-state level of cathepsin
B was lower in HCT 116 cells compared to HKh-2 cells, a
finding consistent with HCT 116 cells secreting higher levels
of cathepsin B and exhibiting a higher percentage of peri-
cellular cathepsin B activity than did HKh-2 cells. Thus, active
K-ras appears to modulate cathepsin B trafficking and se-
cretion in these cells. A functional role for ras in cathepsin B
distribution has already been established in breast cancer
[52], melanoma [53], and osteoclast [54] cell lines. Mutations
in K-ras have been correlated to an upregulation in cathepsin
B expression and activity in colorectal carcinoma cell lines
Figure 5. Distribution of LAMP-1, b-gal, caveolin-1, and cathepsin B in
sucrose gradient fractions of HCT 116 cells. Equal volume aliquots of HCT
116 sucrose gradient fractions illustrated in Figure 4A were subjected to SDS-
PAGE; immunoblotted for LAMP-1, h-gal, caveolin-1, and cathepsin B; and
the protein bands were analyzed by densitometry. The graphs represent the
distribution of these proteins within the sucrose gradient fractions (expressed
as AU/mm2).
Cathepsin B in Tumor Cell Caveolae Cavallo-Medved et al. 515
Neoplasia . Vol. 5, No. 6, 2003
[55] and primary human colorectal carcinomas [56]. In addi-
tion, Kim et al. [56] reported that a mutation in K-ras or an
expression of altered forms of N-ras protein increases the
tumorigenicity of colorectal carcinomas by inducing the
expression of both cathepsin B and cathepsin L. Expression
and activity of mature cathepsin B on the plasma membrane
of H-ras–transformed MCF-10 breast epithelial cells also
have been shown to be upregulated without alterations in
cathepsin BmRNA levels [23]. Thus, modulation of K-ras and
H-ras expression appears to increase the trafficking of active
cathepsin B to the cell surface, which in turn contributes to
the invasive potential of these cells. A recent study from our
laboratory using Matrigel (BD Biosciences, San Diego, CA)
invasion assays confirmed that HCT 116 cells are more
invasive than HKh-2 cells, and inhibitor studies indicated that
cathepsin B is involved in this invasion [13]. Our current data
also show that the activation of K-ras in HCT 116 cells
increases the expression of caveolin-1, the major structural
protein of caveolae, and p11, a binding partner for cathepsin
B. We hypothesize that in these colon cancer cells, the
modulation of caveolin-1 and p11 expression by active
K-ras may regulate the increase in cathepsin B trafficking
to, and activity at, the cell surface.
Upregulation of p11 has been linked to tumorigenicity
and malignancy of various cell lines [42,57]. On the other
hand, the role of caveolin-1 in tumor cells remains contro-
versial. The caveolin-1 gene is located on human chromo-
some 7q31.1 [58], a region frequently deleted in human
breast cancer [59]. Caveolin-1 was identified as one of 26
gene products that are downregulated in breast cancer
cells and, as such, has been suggested to be a potential
tumor suppressor [60]. Evidence also shows that the
transformation of NIH 3T3 fibroblasts with activated v-abl
or H-ras reduces caveolin-1 expression, which in turn leads
to the loss of anchorage-dependent growth and the ability
of these cells to form foci on soft agar [61]. Nonetheless,
several observations argue against caveolin-1 as a tumor
suppressor. Our current data demonstrate that the expres-
sion of caveolin-1 is upregulated in the more invasive HCT
116 colon cancer cells. Caveolin-1 overexpression is seen
in primary and metastatic prostate carcinomas [62,63],
invasive ductal breast carcinomas [62], high-grade bladder
Figure 6. Identification of uPA and uPAR in caveolae of human colorectal carcinoma cells. Equal amounts of protein for HCT 116 and HKh-2 cells were subjected
to subcellular fractionation on a sucrose gradient after homogenization in sodium carbonate buffer, pH 11.0 (see Materials and Methods section). Fractions were
collected from the top of the gradient and equal volume aliquots were analyzed by SDS-PAGE and immunoblotted for anti –human uPAR (A) and anti –human uPA
(B). Densitometric analysis of the uPAR and uPA protein bands from HCT 116 and HKh-2 fractions was performed and presented as percent uPAR and uPA in
individual fractions as a function of the total (sum of fractions 2–11) and percent uPAR and uPA distributed into two major fractions: caveolae (sum of fractions
2–6) and noncaveolae (sum of fractions 7–11).
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cancers [64], and advanced-stage ovarian tumors [65].
Moreover, a positive correlation has been observed be-
tween caveolin-1 and caveolae expression and multidrug
resistance of colon, breast, ovarian, and lung cancer cell
lines [66–68]. In colon and prostate cancers, upregulation
of caveolin-1 is believed to contribute to their invasive
potential [69,70]. A study by Fine et al. [69] revealed that
the expression of caveolin-1 is elevated in colon adenocar-
cinomas in comparison to normal colonic epithelium and
adenomas. In addition, they reported a more diffuse cyto-
plasmic staining pattern for caveolin-1 in these tumor cells
instead of the typical membranous pattern, thus suggesting
alterations in the intracellular trafficking of caveolin-1. Al-
though studies by Bender et al. [67] reported higher levels
of caveolin-1 in normal colon tissues compared to colon
carcinoma cell lines, they did suggest that the initial down-
regulation of caveolin-1 in colon cancer cells may be
reversible because they observed an upregulation of cav-
eolin-1 in metastatic colon carcinoma cells in comparison to
their parental counterparts. Such results imply a dual role
for caveolin-1: one as a tumor suppressor during early
tumor development, and another as a tumor promoter
during late-stage tumorigenesis and metastasis.
During the progression of colon cancer, active cathepsin
B is redistributed to the basal plasma membrane, and
expression of the enzyme is associated with a shortened
survival [20,21]. The present study is the first to identify
caveolae as a site for association of active cathepsin B with
the cell surface of colorectal carcinoma cells. Caveolae are
highly lipid-rich subdomains of the plasma membrane that
are believed to play roles in endocytosis, cholesterol trans-
port, and cell signaling events [71]. More recently, caveolae
have been linked to cell surface proteolysis. The colocaliza-
tion of MMP-2, its activator MT1-MMP, a proposed receptor
avh3, and the inhibitor TIMP-2 with caveolin-1 implicates
caveolae as a site to restrict proteolysis of the matrix to a
limited microenvironment at the cell surface [29,30]. In
addition, the clustering of uPAR and its ligand uPA in
caveolae has been shown to enhance the activation of
plasminogen at the cell surface [28], a process that is also
involved in cell invasion. Although uPA and uPAR have
previously been detected on the surface of HCT 116 cells
[35], in the present study, we identify these proteins specif-
ically in caveolae of these cells. The localization of uPA,
uPAR, and cathepsin B to caveolae of HCT 116 cells is
interesting as cathepsin B has been reported to activate both
soluble and membrane-bound pro-uPA [15–17]—an early
event associated with proteolytic cascades involved in tumor
invasion. Studies conducted in our laboratory using a novel
confocal assay showed pericellular degradation of quenched
fluorescent type IV collagen (DQ collagen IV) by living BT20
breast cancer cells [12]—a degradation that involves a
cascade of proteolytic enzymes including cathepsin B, plas-
minogen cascade serine proteases, and MMPs. These
assays have also been performed using living HCT 116
and HKh-2 cells and show enhanced pericellular degradation
of DQ collagen IV by HCT 116 cells—degradation that can
be reduced by protease inhibitors [13]. Increased expression
of uPAR on the surface of HCT 116 cells compared to HKh-2
cells has also been shown to contribute to increased laminin
degradation by these cells [35]. The fact that active cathep-
sin B, uPA, and uPAR were detected in the caveolae of HCT
116 cells suggests a functional role for caveolae-associated
cathepsin B in tumor cell invasion of colorectal carcinoma
cells, possibly in coordination with the uPA/uPAR system
and MMPs.
The mechanism(s) by which cathepsin B binds to the
extracellular surface of tumor cells currently remains un-
known. Procathepsin B was found to bind directly to p11,
and mature single-chain and double-chain forms of cathep-
sin B were also found in membrane extracts that contain both
the light and heavy chains of AIIt [34]. Previous reports have
shown colocalization of p36 and p11 in the caveolae of
various cell lines including endothelial and MDCK cells
[31,32]. We also detected p11 and p36 in the caveolae of
HCT 116 cells, thus strongly implicating AIIt as a potential
binding protein for caveolae-associated cathepsin B in these
cells. As a membrane protein, AIIt is believed to act as a
receptor for many different ligands such as the ECM proteins
collagen I and tenascin C, as well as proteases including
plasmin(ogen), tPA, and cathepsin B (for review, see Ref.
[72]). Both p36 [73] and p11 [74] were shown to bind
plasminogen and stimulate its activation via a tPA-depen-
dent event, resulting in cell surface matrix degradation and
invasion through the ECM [75]. In tumor cells, the AIIt-
dependent associations between ECM proteins and
enzymes that degrade them appear to facilitate a regulated
modification and turnover of the ECM, essential for tumor
invasion. In support of this hypothesis, Choi et al. [42] have
demonstrated that upregulating the expression of p11 in
HT1080 fibrosarcoma cells increases plasmin production
and invasiveness. Our data show that activation of K-ras
upregulates the expression of p11 and the distribution of p11
to caveolae of colon cancer cells. The expression of p11 in
caveolae of HCT 116 cells appears to correlate with an
increase in trafficking of cathepsin B and uPA to caveolae
of these cells. Thus, we suggest that the presence of p11 as
a binding partner for cathepsin B in the caveolae may serve
to increase the interaction between cathepsin B and uPA/
uPAR, and thus initiate proteolytic cascades involved in
tumor cell invasion. Future experiments, however, will be
required to elucidate the mechanism(s) for and functional
consequences of cathepsin B trafficking to the caveolae.
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